Stockreport

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

AnaptysBio, Inc.  (ANAB) 
Last anaptysbio, inc. earnings: 3/2 08:45 am Check Earnings Report
US:NASDAQ Investor Relations: ir.anaptysbio.com/investor-relations
PDF Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024Top-line Phase 2b data anticipated for rosnilimab, our PD-1 ag [Read more]